menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Maximizing PH Care Using Risk Assessment to Improve Outcomes

Explore the new thinking behind revised risk stratification and the developing concepts of pulmonary arterial hypertension treatment.

Live Broadcast
1.00 available credits
Information
November 08, 2022
12:00 PM - 01:00 PM EST
Virtual
ReachMD Healthcare Image
Details
Presenters
Comments
  • Overview

    In the management of the pulmonary arterial hypertension (PAH) patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, based on the registries, from which the modern risk assessment models have been developed, it’s clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there’s a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy and lung transplantation.

  • Target Audience

    This activity has been designed to meet the educational needs of physicians, registered nurses, pharmacists and other healthcare professionals involved in the care of patients with pulmonary hypertension.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:
    1. Discuss the importance of periodic risk assessment for PAH
    2. Debate the expansion of risk stratification in PAH from 3 to 4 levels
    3. Review the goals of PAH therapy and the potential application of triple combination therapy to achieve low-risk status in the PAH patient
    4. Discuss the balance between more advanced and aggressive therapeutic approaches and the trade-off of greater side effects
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    Global Learning Collaborative (GLC) designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) designates this activity for 1.0 hour of Nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for 1.0 contact hour 0.1 CEUs by Global Learning Collaborative (GLC). GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    The Universal Activity Number for this program is JA0006235-9999-22-025-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    The following faculty has reported relationships with ineligible companies:

    Vallerie V. McLaughlin, MD, faculty for this educational event, receives research funds from Acceleron, Janssen, Sonovie and United Therapeutics; and receives consulting fees from Acceleron, Aerovate, Altavant, Bayer, Caremark LLC, Civi Biopharma Inc., Corvista, Gossamer Bio, Janssen, Merck and United Therapeutics.

    All the relevant financial relationships for these individuals have been mitigated.

    The following reviewers/planners have reported no relationships with ineligible companies:

    Dixon W. Wilde, PhD., FAHA, planner for this educational event, has no relevant financial relationships with ineligible companies.

    Chad McQueen, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated.

  • Provider(s)/Educational Partner(s)

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Commercial Support

    This activity is supported by educational grants from Actelion Pharmaceuticals US, Division of Janssen Pharmaceuticals and United Therapeutics Corporation.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Details
Presenters
Comments
Recommended
  • Overview

    In the management of the pulmonary arterial hypertension (PAH) patient, the use of risk assessment algorithms has become de rigueur for the regular determination of disease progression and the effectiveness of treatment. However, based on the registries, from which the modern risk assessment models have been developed, it’s clear that the majority of patients fall into the intermediate-risk category. And yet, within this broad category, there’s a spectrum of disease severity, medical treatment need, and survivorship. Using risk assessment effectively in the modern era will rely on a rethinking of how to use risk assessment and adjusting disease management strategies appropriately. This program explores new ideas in the use and application of risk assessment protocols and the impact these have on the use of multimodal, combination therapy and lung transplantation.

  • Target Audience

    This activity has been designed to meet the educational needs of physicians, registered nurses, pharmacists and other healthcare professionals involved in the care of patients with pulmonary hypertension.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:
    1. Discuss the importance of periodic risk assessment for PAH
    2. Debate the expansion of risk stratification in PAH from 3 to 4 levels
    3. Review the goals of PAH therapy and the potential application of triple combination therapy to achieve low-risk status in the PAH patient
    4. Discuss the balance between more advanced and aggressive therapeutic approaches and the trade-off of greater side effects
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    Global Learning Collaborative (GLC) designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) designates this activity for 1.0 hour of Nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for 1.0 contact hour 0.1 CEUs by Global Learning Collaborative (GLC). GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    The Universal Activity Number for this program is JA0006235-9999-22-025-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    The following faculty has reported relationships with ineligible companies:

    Vallerie V. McLaughlin, MD, faculty for this educational event, receives research funds from Acceleron, Janssen, Sonovie and United Therapeutics; and receives consulting fees from Acceleron, Aerovate, Altavant, Bayer, Caremark LLC, Civi Biopharma Inc., Corvista, Gossamer Bio, Janssen, Merck and United Therapeutics.

    All the relevant financial relationships for these individuals have been mitigated.

    The following reviewers/planners have reported no relationships with ineligible companies:

    Dixon W. Wilde, PhD., FAHA, planner for this educational event, has no relevant financial relationships with ineligible companies.

    Chad McQueen, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated.

  • Provider(s)/Educational Partner(s)

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Commercial Support

    This activity is supported by educational grants from Actelion Pharmaceuticals US, Division of Janssen Pharmaceuticals and United Therapeutics Corporation.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Schedule7 Dec 2022